AOD-9604
Also known as: AOD9604 · Anti-Obesity Drug 9604 · HGH Fragment 176-191
AOD-9604 activates beta-3 adrenergic receptors in adipose tissue, stimulating lipolysis (breakdown of stored fat) and inhibiting lipogenesis (fat storage). Unlike full HGH, it does not significantly stimulate IGF-1 production or affect blood glucose levels, making it safer for diabetics. It...
What It Is
AOD-9604 activates beta-3 adrenergic receptors in adipose tissue, stimulating lipolysis (breakdown of stored fat) and inhibiting lipogenesis (fat storage). Unlike full HGH, it does not significantly stimulate IGF-1 production or affect blood glucose levels, making it safer for diabetics. It mimics the fat-burning activity of the hGH C-terminal fragment without the growth-promoting or insulin-desensitizing effects. It may also have mild regenerative effects on cartilage.
Supplies Needed
Reconstitution solvent
Subcutaneous injection
Sterilization
Storage
Store at -20C for up to 2 years. Stable at 2-8C for up to 6 months.
Refrigerate at 2-8C; use within 30 days.
This information is provided for educational and research purposes only. Not approved for human consumption by the FDA or any regulatory body. Always consult a qualified medical professional.
Dosing Protocols
Timing: Morning, fasted (30 minutes before eating). Inject into abdominal subcutaneous fat for localized effect
↓ Apply these values to the reconstitution calculatorTiming: Morning, fasted. Standard dose studied in clinical trials; 500 mcg/day is top studied dose
↓ Apply these values to the reconstitution calculatorTiming: Morning fasted and/or pre-workout. Higher doses for accelerated fat loss; stack with Ipamorelin for body recomposition
↓ Apply these values to the reconstitution calculatorWeekly Timeline
| Week | Expected Effects |
|---|---|
| Week 1 | Mild increase in energy expenditure; subtle reduction in hunger |
| Week 2 | Early fat mobilization; improved definition in abdominal area |
| Week 4 | Noticeable fat loss particularly in stubborn adipose areas |
| Week 8 | Significant reduction in body fat percentage; improved body composition |
| Week 12 | Maximum fat loss effects achieved; continued body recomposition |
Reconstitution Calculator
1 unit on U-100 syringe = 0.01 mL · Always label your vial after reconstitution
Injection Technique & Reconstitution
- Remove flip-top cap from the vial
- Swab rubber stopper with alcohol swab and allow to dry
- Draw 2 mL bacteriostatic water into syringe
- Inject BAC water slowly down the vial wall
- Gently swirl until dissolved
- Label with date; refrigerate at 2-8C
Use our free peptide calculator to get the exact syringe units for your vial size and dose.
Mechanism of Action
AOD-9604 activates beta-3 adrenergic receptors in adipose tissue, stimulating lipolysis (breakdown of stored fat) and inhibiting lipogenesis (fat storage). Unlike full HGH, it does not significantly stimulate IGF-1 production or affect blood glucose levels, making it safer for diabetics. It mimics the fat-burning activity of the hGH C-terminal fragment without the growth-promoting or insulin-desensitizing effects. It may also have mild regenerative effects on cartilage.
Key Research Papers
Demonstrated dose-dependent reduction in body fat in obese mice treated with AOD-9604 without affecting blood glucose or IGF-1 levels.
View on PubMed →Stacks Well With
Combines fat-burning of AOD-9604 with GH pulse from Ipamorelin for body recomposition - lose fat while preserving/building lean mass.
Complementary fat loss mechanisms - GLP-1 receptor agonist adds appetite suppression and metabolic improvements alongside AOD-9604's direct lipolysis.
Frequently Asked Questions
AOD-9604 is primarily used for fat loss. It is the C-terminal fragment of human growth hormone responsible for fat-burning, extracted and synthesized to provide lipolytic effects without the growth-promoting or insulin-desensitizing effects of full HGH.
AOD-9604 is considered safer for diabetics than full HGH because it does not significantly affect blood glucose or IGF-1 levels. However, consult a physician before use.
Most users begin noticing changes in body composition within 4-6 weeks, with more significant fat loss at 8-12 weeks of consistent use combined with a caloric deficit.
Legal Status by Region
This information is provided for educational and research purposes only. Not approved for human consumption by the FDA or any regulatory body. Always consult a qualified medical professional.